Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biogaia Adr Class B BIOGY

Healthcare Biotechnology
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics... see more

Recent & Breaking News (PINL:BIOGY)

Cleave Biosciences Initiates Phase 1 Clinical Trial of CB-5083 in Patients with Advanced Solid Tumors

PR Newswire January 8, 2015

Trovagene and City of Hope Collaborate To Monitor EGFR Mutational Status in Lung Cancer Patients

PR Newswire January 8, 2015

Benitec Announces Publication Of Independent Research Supporting Tribetarna(TM) For Additional Cancer Indications

PR Newswire January 8, 2015

Regulus Announces Key Goals Under its 'Clinical Map Initiative' for 2015

PR Newswire January 8, 2015

First Radiotherapy Treatment Planned Using Varian's RapidPlan Takes Place at Leading UK Cancer Center

PR Newswire January 8, 2015

Edge Therapeutics Announces Appointment of Renu Vaish, M.S. as Vice President, Regulatory Affairs

Business Wire January 8, 2015

Transgenomic to Present at OneMedForum San Francisco 2015 Conference

Business Wire January 8, 2015

Alnylam Launches "Alnylam 2020" Guidance for Advancement and Commercialization of RNAi Therapeutics

Business Wire January 8, 2015

Novocure Announces $100 Million Term Loan Agreement with Pharmakon Advisors

Business Wire January 8, 2015

Genervon Announces ALS Compassionate Use Results

Business Wire January 8, 2015

Aileron Therapeutics Appoints Evan Lippman as Chief Financial and Business Officer

Business Wire January 8, 2015

Rosetta Genomics Announces Launch of Admera Health's Sequencing-Based Oncology Tests

Business Wire January 8, 2015

Moderna Launches New Venture Valera LLC for Infectious Diseases

PR Newswire January 8, 2015

ANGLE plc ("ANGLE" Or "The Company") Corporate Collaboration With Large Pharmaceutical Company

PR Newswire January 8, 2015

Willie L. Brown, Jr. Joins the Board of Directors of Global Blood Therapeutics

Marketwired January 8, 2015

Indi(R) Appoints Douglas Sanders CFO

Marketwired January 8, 2015

Surface Oncology Announces $35 Million Series A Financing to Advance Next-Generation Cancer Immunotherapies

Business Wire January 8, 2015

First Patient Successfully Transplanted with Cryopreserved (Frozen) NiCord® in Gamida Cell's Ongoing Phase I/II Clinical Trial for Blood Cancers

PR Newswire January 8, 2015

Galena Biopharma Provides 2015 Outlook

GlobeNewswire January 8, 2015

Galena Biopharma Provides 2015 Outlook

GlobeNewswire January 8, 2015